The biotech game just got louder. Emeryville-based Ansa Biotechnologies closed a $54.4M oversubscribed Series B. $45.2M closed and $9.2M in commitments, led by Cerberus Ventures with fresh backing from Fall Line Capital, AIM13, and Black Opal Ventures, plus returning believers Blue Water Life Science Advisors and Altitude Life Science Ventures. That’s not just fundraising, it’s proof that gravity bends toward whoever owns the next frontier in DNA writing.
Founded in 2018 by Dan Lin-Arlow, PhD, and Sebastian Palluk, PhD, Ansa built its platform on a brutal reality: chemical DNA synthesis has hit a ceiling. Short fragments, high error rates, toxic waste, it’s like forcing Netflix to buffer on dial-up. Enter Ansa’s enzymatic DNA synthesis. By harnessing polymerase-nucleotide conjugates, their “dipping” synthesizer adds bases with surgical precision, eco-friendly chemistry, and scale that makes old methods look prehistoric. The payoff: clonal, sequence-perfect DNA up to 50 kb, unlocking lengths that were once fantasy.
The timing couldn’t be sharper. Commercial launch came in April 2025 with DNA up to 7.5 kb, and by September, Ansa rolled out 50 kb constructs under an “on-time or free” guarantee. Reliability isn’t sexy until you realize every therapeutic, vaccine, and agrigenomics breakthrough depends on it. Ansa didn’t tinker in stealth, they delivered, fast. From 600 bp to 7.5 kb to 50 kb in under 1 year.
At the helm sits CEO Jason T. Gammack, flanked by co-founders Dan Lin-Arlow and Sebastian Palluk, and a leadership bench that keeps execution tight: Dave Bullis (Strategic Marketing), Marcos Urias (Manufacturing), John Trust (Finance), and Nick Hurt (General Counsel & IP). On the board, Cerberus Ventures’ Chenny Zhang and Fall Line Capital’s Yanniv Dorone, PhD, join the roster, capital meets conviction.
This $54.4M isn’t just fuel, it’s acceleration. Scaling U.S. manufacturing to meet global demand. Investing in customer experience so the science delivers as promised. Building strategic partnerships while prototyping desktop synthesizers that bring DNA writing straight to the bench. Expanding beyond 50 kb, driving costs down, speeding timelines up.
The synthetic DNA market is measured in billions, but the real prize is trust. Ansa Biotechnologies is proving DNA doesn’t have to come with caveats. This round validates that the bottlenecks are breaking, and the future of biotech is about speed, scale, and sequence perfection.
